Brussels, 20 January 2008 -- World leader in barrier protection, Ansell Healthcare has launched the Gammex® PF XPTM (eXtra Protection) following intensive research into hazards arising from the reconstitution and manipulation of cytostatics. The new model - a member of the successful Gammex® family of gloves - provides hospital pharmacists with superior protection against cytostatic permeation and unparalleled levels of comfort during the preparation of cytostatics.
The global burden of cancer is constantly increasing. According to figures from the World Health Organization, there were 3.2 million new cases of cancer in 2006 (up from 2.9 million in 2004), most of them in the EU. That number is expected to rise to 15 million by 2020. Cytostatics, the drugs used in chemotherapy, play a pivotal role in the treatment of all these cancer patients. As the literature contains data regarding the mutagenic, carcinogenic and teratogenic effects of these drugs, all responsible bodies agree that the risks must be minimized. The highest barrier protection is therefore required for everyone exposed to cytostatics.
Deep research into cytostatics
Committed to improving barrier protection for healthcare workers and patients alike, Ansell Healthcare has been carrying out in-depth research into glove permeation by cytostatics for some time now. A first result was the Ansell Cytostatics Permeation Programme (ACPP), a methodology developed jointly with the Universite Catholique de Louvain (Belgium) to measure the dynamic cytostatics permeation level of medical gloves. Tests with the ACPP device show that all Ansell gloves provide much better protection than the accepted limit imposed by existing European norms. Based on the knowledge amassed on the issue, Ansell Healthcare has now developed a glove for a very specific application within this high-risk environment: the reconstitution of cytostatics. Hospital pharmacists who prepare the chemotherapy drugs are generally assumed to be one of the occupational groups with the highest potential exposure to cytostatics.
Optimal protection and comfort
10% thicker than its other Gammex® counterparts and with a low risk of pinholes (AQL 0.65), the new Gammex® PF XPTM ensures superior impermeability. This has been proven in ACPP tests: the new Gammex® withstands a selection of cytostatics for up to 60 minutes, even after exposure to ethanol which can degrade latex and result in faster permeation rates.
The Gammex® PF XPTM combines this unequalled protection with the sensitivity and comfort level so typical of the Gammex® range. As the glove feels like a second skin, hand fatigue is minimized. To ensure easy donning, even with damp hands, Ansell incorporated a polyurethane inner coating that combines hydrophilic and hydrophobic components. In addition, the glove surface is designed to secure safe handling of laboratory equipment and the adhesive cuff band prevents the cuff from rolling down. Finally, the indigo-blue colour comes in handy to avoid confusion when having to choose or change gloves before starting this high-risk application.
With latex sensitization as one of Ansell's major concerns, Ansell has done its utmost to reduce the risk of latex sensitization in this glove. The Gammex® PF XPTM is manufactured using Protein and Endogenous Allergen Reduction Leaching (PEARL) technology, which produces a glove with extremely low extractible proteins. The risk of contact dermatitis is reduced because the accelerator is completely consumed during the manufacturing process.
"All the above comfort features foster user acceptance and will, as such, ensure that more pharmacists are adequately protected against cytostatics," said Holger Fürstenberg, Marketing Director, Professional Healthcare Europe, upon the launch of the new Gammex® PF XPTM. "For Ansell, this new glove is a perfect addition to our successful Gammex range of surgical gloves, which we're constantly expanding with more innovative features."
Ansell Limited is a global leader in barrier protective products. With operations in the Americas, Europe and Asia, Ansell employs more than 11,000 people worldwide and holds leading positions in the natural latex and synthetic polymer glove and condom markets. Ansell operates in three main business segments: Occupational Healthcare, supplying hand protection to the industrial market; Professional Healthcare, supplying surgical and examination gloves to healthcare professionals; and Consumer Healthcare, supplying condoms and consumer hand protection. Information on Ansell and its products can be found at http://www.ansell.eu
For more information, please contact:
Global Communications Director, Ansell Healthcare
Tel: +32 (0)2 528 75 68; Cell. +32 (0)478 33 56 32